TRT & Red Blood Cell Production: Benefits & Risks

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

TRT stimulates red blood cell production, which can treat anemia but also lead to erythrocytosis. Careful monitoring of hematocrit levels is essential to manage this common side effect.

TRT and Red Blood Cell Production

Testosterone Replacement Therapy (TRT) often leads to an increase in red blood cell (RBC) production, a physiological response that can be both beneficial and, if unchecked, a potential concern. This effect is well-documented and a routine aspect of monitoring for men undergoing TRT.

Testosterone directly stimulates erythropoiesis, the process of RBC formation, primarily by increasing the production of erythropoietin (EPO) in the kidneys. EPO is a hormone that signals the bone marrow to produce more red blood cells. This mechanism is why TRT can be an effective treatment for certain types of anemia in hypogonadal men, as highlighted by studies showing significant increases in hemoglobin levels in anemic men treated with testosterone (Snyder et al., 2017).

The increase in RBCs is typically measured by monitoring hematocrit (Hct) and hemoglobin (Hb) levels. A moderate increase in these parameters can be beneficial, improving oxygen-carrying capacity and potentially enhancing energy levels and exercise performance. For men with anemia of chronic disease or unexplained anemia, TRT can resolve this condition, leading to improved vitality.

However, excessive RBC production, known as erythrocytosis or polycythemia, is the most common adverse event associated with TRT. When hematocrit levels rise too high (generally above 50-52%), the blood becomes thicker, increasing its viscosity. This can elevate the risk of cardiovascular events such as stroke, heart attack, and deep vein thrombosis. Bachman et al. (2013) extensively documented this phenomenon, noting that erythrocytosis is a frequent side effect in clinical practice.

Unlike the improvements in muscle mass or libido, which are generally dose-dependent and desirable, erythrocytosis requires careful management. The risk is higher with injectable forms of testosterone, particularly those with longer half-lives, due to more pronounced peaks in testosterone levels. Transdermal gels or pellets tend to have a more stable pharmacokinetic profile and may carry a lower risk of significant erythrocytosis.

Monitoring is crucial. Physicians typically check hematocrit and hemoglobin levels at baseline, then at 3-6 months after initiating TRT, and annually thereafter. If hematocrit consistently exceeds the upper limit of normal, strategies to manage erythrocytosis include reducing the testosterone dose, increasing the frequency of injections (to flatten peak levels), or switching to a different administration method. Therapeutic phlebotomy (blood donation) is also a common and effective intervention to reduce RBC mass and blood viscosity, often performed when hematocrit approaches 54%.

In clinical practice, we often see a patient whose hematocrit rises from 45% pre-TRT to 51% after six months on 100mg testosterone cypionate weekly. This is a common and manageable increase. However, if another patient on the same dose sees his hematocrit jump to 55%, we would immediately intervene, perhaps by reducing his dose to 80mg weekly or recommending a therapeutic phlebotomy to bring his levels back into a safer range. This proactive management is key to safely continuing TRT.

The practical takeaway is that while TRT can improve anemia and oxygen transport, it requires diligent monitoring of red blood cell parameters. Regular blood tests are not merely bureaucratic hurdles; they are essential for ensuring the safety and efficacy of your therapy. Discuss any concerns about blood thickness, fatigue, or headaches with your physician, as these can be signs of elevated hematocrit requiring intervention.